NilotinibIn the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase

被引：0
|
作者：
Karly P. Garnock-Jones
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs | 2011年 / 71卷
关键词：
Imatinib; Chronic Myeloid Leukaemia; Nilotinib; Anagrelide; Major Molecular Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Nilotinib is an effective first-line treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic phase. It is an aminopyrimidine-based, high-affinity inhibitor of the tyrosine kinase activity of BCR-ABL. It thus decreases ABL-associated cell proliferation and kinase autophosphorylation.
引用
收藏
页码：1579 / 1590
页数：11
相关论文
共 50 条
  • [1] Nilotinib In the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase
    Garnock-Jones, Karly P.
    DRUGS, 2011, 71 (12) : 1579 - 1590
  • [2] Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase
    Saydam, Guray
    Haznedaroglu, Ibrahim Celalettin
    Kaynar, Leylagul
    Yavuz, Akif S.
    Ali, Ridvan
    Guvenc, Birol
    Akay, Olga M.
    Baslar, Zafer
    Ozbek, Ugur
    Sonmez, Mehmet
    Aydin, Demet
    Pehlivan, Mustafa
    Undar, Bulent
    Dagdas, Simten
    Ayyildiz, Orhan
    Akkaynak, Diyar Z.
    Dag, Ilkiz M.
    Ilhan, Osman
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (14) : 1851 - 1858
  • [3] Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia
    Saydam, Guray
    Haznedaroglu, Ibrahim C.
    Kaynar, Leylagul
    Yavuz, Akif S.
    Ali, Ridvan
    Guvenc, Birol
    Akay, Olga M.
    Baslar, Zafer
    Ozbek, Ugur
    Sonmez, Mehmet
    Aydin, Demet
    Pehlivan, Mustafa
    Undar, Bulent
    Dagdas, Simten
    Ayyildiz, Orhan M.
    Akkaynak, Diyar Z.
    Dag, Ilkiz M.
    Ilhan, Osman
    BLOOD, 2013, 122 (21)
  • [4] High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
    Kantarjian, H
    Talpaz, M
    O'Brien, SS
    Garcia-Manero, G
    Verstovsek, S
    Giles, F
    Rios, MB
    Shan, JQ
    Letvak, L
    Thomas, D
    Faderl, S
    Ferrajoli, A
    Cortes, J
    BLOOD, 2004, 103 (08) : 2873 - 2878
  • [5] Cost-effectiveness of nilotinib versus imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph plus ) chronic myeloid leukemia in the chronic phase (CML-CP): Swedish perspective
    Ovanfors, A.
    Stephens, J.
    Snedecor, S. J.
    Patel, D.
    Ji, X.
    Carpiuc, K. T.
    Coombs, J.
    Botteman, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] COST-EFFECTIVENESS OF NILOTINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE (CML-CP) IN RUSSIAN FEDERATION
    Yagudina, R.
    Kulikov, A.
    Komarov, I
    VALUE IN HEALTH, 2012, 15 (07) : A426 - A426
  • [7] TREATMENT, RESPONSE, AND OUTCOME IN UNSELECTED ELDERLY PATIENTS WITH NEWLY DIAGNOSED, CHRONIC PHASE (CP), PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA
    Gugliotta, G.
    Stagno, F.
    De Vivo, A.
    Spitalieri, A.
    Castagnetti, F.
    Fabbiano, F.
    Capodanno, I.
    Mannina, D.
    Salvucci, M.
    Antolino, A.
    Marasca, R.
    Musso, M.
    Crugnola, M.
    Consoli, U.
    Trabacchi, E.
    Musolino, C.
    Cavazzini, F.
    Longo, G.
    Tosi, P.
    Cardinale, G.
    Rizzo, M.
    Soverini, S.
    Martinelli, G.
    Cavo, M.
    Vigneri, P.
    Rosti, G.
    Di Raimondo, F.
    Baccarani, M.
    HAEMATOLOGICA, 2016, 101 : 739 - 740
  • [8] First-line treatment of chronic myeloid leukaemia
    O'Dwyer, Michael
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2010, 1 (01) : 15 - 22
  • [9] Dasatinib A Review of its Use in the Treatment of Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
    McCormack, Paul L.
    Keam, Susan J.
    DRUGS, 2011, 71 (13) : 1771 - 1795
  • [10] DasatinibA Review of its Use in the Treatment of Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
    Paul L. McCormack
    Susan J. Keam
    Drugs, 2011, 71 : 1771 - 1795
12345